From the trial currently going forward in Arkansas:
Wyeth researchers in 1983 told of studies focusing on the breast-cancer risks associated with what became the company's Prempro hormone-replacement drug may come back to haunt the drugmaker says a Memo introduced at a trail on the drug.
The FDA's requested Prempro review ``would be very costly and would take many years,'' researchers said in the memo. ``In fact, the result of the studies might prove to be embarrassing.''
For more, go here.